To determine whether BDNF can serve as a biomarker for MS, a comparatively large cohort research found that the level of BDNF can be detected to have a difference between MS patients and healthy controls, with mean BDNF levels in the former were lower by 8% than the latter. The gene discussed is BDNF; the disease is myeloid sarcoma.